SOURCE: Smith & Nephew PLC

February 09, 2006 06:16 ET

Smith & Nephew PLC announce Management Appointments

London, UK -- (MARKET WIRE) -- February 9, 2006 --

Smith & Nephew senior management appointments

9 February 2006

Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announced today that it has made three new Business Unit President appointments with immediate effect.

Smith & Nephew's Orthopaedics business has grown strongly in the last five years, with performance consistently ahead of its markets. To develop this business further, we are now identifying two separate business units; Orthopaedic Reconstruction and Orthopaedic Trauma (including Clinical Therapies). This change is at the heart of our strategy to focus our businesses on the markets and customers that they serve.

Scott Flora, currently Senior Vice-President and General Manager of the Reconstructive Division, is promoted to President Orthopaedic Reconstruction. Scott has over 20 years experience in the medical device industry including working with companies such as Johnson & Johnson. He joined Smith & Nephew in 1986 as a sales representative and was progressively promoted becoming Senior Vice-President of Trauma and Clinical Therapies Division in 2003. In March 2005 he was appointed to his current role.

Mark Augusti is promoted to President Orthopaedic Trauma and Clinical Therapies. Mark started his career in sales with GE Medical Systems and spent 13 years there in a number of roles based in the US and Asia. He joined Smith & Nephew in April 2003 as Vice President of Global Marketing for the Trauma Division and was promoted to Senior Vice-President and General Manager Trauma Division in March 2005.

After 30 years with Smith & Nephew, the last seven years as President of Advanced Wound Management, Jim Dick will be retiring in the summer of this year.

Joe Woody, currently the Vice President and General Manager of the Clinical Therapies Division, has been appointed as Jim's successor as President of Advanced Wound Management. Joe has 20 years experience in marketing and sales and worked for Alliance Imaging, Acuson and GE Medical Systems before joining Smith & Nephew in 2003. Under his leadership Clinical Therapies has grown rapidly into a significant business. Joe will re-locate to the UK to take up his new role.

Sir Christopher O'Donnell, Chief Executive of Smith & Nephew, commenting on these appointments today said:

"Smith & Nephew's Orthopaedics business has grown substantially in recent years with performance consistently ahead of its markets. As a consequence of segmenting our Orthopaedics business we are able to promote two highly talented people to President. The appointment of Scott Flora and Mark Augusti coincide with an exciting time for these businesses with excellent opportunities for continued above market growth."

"Joe Woody has made a major contribution in leading the excellent growth achieved by Clinical Therapies. We look forward to benefiting from his broad experience in sales and marketing, particularly in the United States, in accelerating growth in our Advanced Wound Management business."

Commenting on Jim Dick's retirement, Christopher O'Donnell added: "Under Jim Advanced Wound Management has evolved into a global leader with strong market positions in all major countries of the world. I would like to thank Jim for his contribution to the Group over many years."

Enquiries


Investors
Sir Christopher O'Donnell          Tel:         +44 (0) 20 7401 7646
Smith & Nephew
Chief Executive

Investors / Media
Liz Hewitt                         Tel:         +44 (0) 20 7401 7646
Smith & Nephew
Group Director Corporate Affairs

About us

Smith & Nephew is a global medical technology business, specialising in Orthopaedics, Endoscopy and Advanced Wound Management products. Smith & Nephew is a global leader in arthroscopy and advanced wound management and is one of the fastest growing global orthopaedics companies.

Smith & Nephew is dedicated to helping improve people's lives. The company prides itself on the strength of its relationships with its surgeons and professional healthcare customers, with whom its name is synonymous with high standards of performance, innovation and trust. The company has over 8,500 employees and operates in 33 countries around the world generating annual sales of $2.6 billion.

                      This information is provided by RNS
            The company news service from the London Stock Exchange